Zim Laboratories consolidated net profit rises 291.30% in the June 2024 quarter

Zim Laboratories consolidated net profit rises 62.16% in the December 2022 quarter

Zim Laboratories Ltd, Skipper Ltd, KFin Technologies Ltd and Tarapur Transformers Ltd are among the other losers in the BSE’s ‘B’ group today, 30 December 2022.

Sintex Plastics Technology Ltd leads losers in ‘B’ group

Zim Laboratories will go ex-bonus in the 2:1 ratio while Precision Wires India will go ex-bonus in the 1:2 ratio. Quint Digital Media will go ex-rights today

Triveni Turbine, 2 others to trade ex-buyback today; Precision Wires India, Zim Labs to go ex-bonus

With a market worth of Rs. 512.51 Cr., Zim Laboratories Ltd. is a small-cap business that operates in the pharmaceutical industry.

Pharma stock is 186% above 52-week-low, record date fixed for 2:1 bonus shares

Drug delivery solution provider ZIM Laboratories Ltd got listed on the National Stock Exchange of India (NSE) today.

#ZIMLaboratories #DalalStreetDebut #NSE #cnbctv18 #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday 

About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. 

You can also connect with CNBC-TV18 News Online
Catch the latest news: https://bit.ly/2YbpXBM

Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/

Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/

You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.cnbctv18.com/minis/

Subscribe to our Channel: https://bit.ly/3nvEcxf

Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News

n18oc_business

ZIM Laboratories Makes D-Street Debut, Gets Listed On National Stock Exchange | #Shorts

With a market valuation of ₹509.10 Cr, Zim Laboratories Ltd. is a small-cap company that engages in the pharmaceutical industry.

Multibagger pharma stock declares 2:1 bonus shares, net profit jumps 182% in Q2

The product is developed using patented Thinoral technology.

ZIM Laboratories announces grant of marketing authorization for ‘Sildenafil 50 mg’ in Spain, Europe

Zim Laboratories consolidated net profit rises 173.95% in the September 2021 quarter

The rating upgrade is on account of significant improvement in the profitability margins and business risk profile in FY2021.

Acuite upgrades ratings on Zim Laboratories’ bank facilities; Stock sheds 1%

Rizatriptan is widely used for relief from Migraine attacks.

ZIM Laboratories receives grant to market Rizatriptan product in Portugal, Europe

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. 